Biotechs such as Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a high local tax bill, a heavy U.S.-based ...

NEW YORK (Reuters) -Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the ...

Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

NEW YORK, April 29 (Reuters) - Gilead Sciences (GILD.O), opens new tab agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying kickbacks to ...

FOSTER CITY, Calif., April 29, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA ...

As the Trump administration stares down diversity programs, this big Peninsula employer is highlighting its efforts.

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...